Rigosertib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rigosertib
Accession Number
DB12146
Description

Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 451.49
Monoisotopic: 451.130087943
Chemical Formula
C21H25NO8S
Synonyms
Not Available
External IDs
  • ON 01910
  • ON-01910

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rigosertib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rigosertib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rigosertib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Rigosertib.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Rigosertib Sodium406FL5G00V592542-60-4VLQLUZFVFXYXQE-USRGLUTNSA-M

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Anisoles / Styrenes / Methoxybenzenes / Phenoxy compounds / Phenylalkylamines / Alkyl aryl ethers / Secondary alkylarylamines / Sulfones
show 7 more
Substituents
Alkyl aryl ether / Alpha-amino acid / Amine / Amino acid / Aminophenyl ether / Aniline or substituted anilines / Anisole / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
67DOW7F9GL
CAS number
592542-59-1
InChI Key
OWBFCJROIKNMGD-BQYQJAHWSA-N
InChI
InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
IUPAC Name
2-[(2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenyl)amino]acetic acid
SMILES
COC1=CC(OC)=C(\C=C\S(=O)(=O)CC2=CC=C(OC)C(NCC(O)=O)=C2)C(OC)=C1

References

General References
Not Available
PubChem Compound
6918736
PubChem Substance
347828442
ChemSpider
5293927
BindingDB
50060917
ChEBI
145417
ChEMBL
CHEMBL1241855
ZINC
ZINC000003942646
PDBe Ligand
6FS
Wikipedia
Rigosertib
PDB Entries
5j18 / 5j2r / 5ov7

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentMDS / Myelodysplastic Syndrome / Refractory anaemia with an excess of blasts / Refractory Anemia With Excess Blasts1
3CompletedTreatmentChronic Myelomonocytic Leukemia / Cytopenias / Myelodysplastic Syndromes (MDS) / Refractory Anemia With Excess Blasts1
3CompletedTreatmentChronic Myelomonocytic Leukemia / MDS / Myelodysplastic Syndromes (MDS) / Refractory anaemia with an excess of blasts1
3CompletedTreatmentPancreatic Adenocarcinoma Metastatic1
2Active Not RecruitingTreatmentMyelodysplastic Syndromes (MDS)1
2CompletedTreatmentAcute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndromes (MDS)1
2CompletedTreatmentAnal Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma / Esophageal Squamous Cell Carcinoma (ESCC) / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lung Squamous Cell Carcinoma / Penile Squamous Cell Carcinoma (PSCC) / Skin Squamous Cell Carcinoma1
2CompletedTreatmentMDS / Myelodysplastic Syndrome / Trisomy 81
2CompletedTreatmentMyelodysplastic Syndrome1
2CompletedTreatmentOvarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0226 mg/mLALOGPS
logP2.64ALOGPS
logP-0.25ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)2.27ChemAxon
pKa (Strongest Basic)5.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.39 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity116.5 m3·mol-1ChemAxon
Polarizability46.32 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 15:28 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates